GeneDx Holdings (WGS) Liabilities and Shareholders Equity (2020 - 2026)

GeneDx Holdings has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $506.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.41% year-over-year to $506.3 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 19.48% YoY), while the FY2025 annual figure was $523.7 million, up 24.88% from the prior year.
• Liabilities and Shareholders Equity retreated to $506.3 million in Q1 2026, from $523.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for WGS reached as high as $933.3 million in Q2 2022 and fell as low as $389.1 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $476.4 million (2023), against an average of $510.3 million.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 431.68% — and 2023, when it slumped 49.66%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $490.9 million in 2022, then retreated by 14.7% to $418.8 million in 2023, then grew by 0.15% to $419.4 million in 2024, then increased by 24.88% to $523.7 million in 2025, then declined by 3.32% to $506.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $506.3 million, $523.7 million, and $493.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.